Notes And Other Explanatory Information [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
Notes and other explanatory information [abstract]
Disclosure of accounting judgements and estimates [text block]
3. CRITICAL ACCOUNTING ESTIMATES
Disclosure of auditors' remuneration [text block]
30. AUDIT FEES
Disclosure of authorisation of financial statements [text block]
The consolidated financial statements were authorized
Disclosure of basis of preparation of financial statements [text block]
2
Disclosure of borrowings [text block]
15. BORROWINGS AND OTHER
Disclosure of cash and cash equivalents [text block]
13. CASH AND CASH EQUIVALENTS
Disclosure of commitments [text block]
27. COMMITMENTS AND CONTINGENT
Disclosure of commitments and contingent liabilities [text block]
26. CONTINGENCIES
Disclosure of credit risk [text block]
4
Disclosure of deferred taxes [text block]
17. DEFERRED TAXES
Disclosure of depreciation and amortisation expense [text block]
(in € thousand)
Disclosure of earnings per share [text block]
24. EARNINGS PER SHARE
Disclosure of effect of changes in foreign exchange rates [text block]
4
Disclosure of entity's operating segments [text block]
5. OPERATING SEGMENTS
Disclosure of events after reporting period [text block]
29. SUBSEQUENT EVENT (AFTER THE END
Disclosure of expenses by nature [text block]
19. EXPENSES BY NATURE
Disclosure of fair value measurement [text block]
4
Disclosure of financial instruments [text block]
4. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT
Disclosure of financial risk management [text block]
4
Disclosure of general information about financial statements [text block]
1. GENERAL INFORMATION
Disclosure of going concern [text block]
3
Disclosure of government grants [text block]
11. TRADE RECEIVABLES AND OTHER
Disclosure of impairment of assets [text block]
7. INTANGIBLE ASSETS
Disclosure of income tax [text block]
23. INCOME TAX EXPENSE
Disclosure of information about employees [text block]
20. EMPLOYEE BENEFIT EXPENSES
Disclosure of information about key management personnel [text block]
28
Disclosure of interest income [text block]
22. FINANCIAL RESULT
Disclosure of investments accounted for using equity method [text block]
9. EQUITY ACCOUNTED INVESTEES
Disclosure of investments other than investments accounted for using equity method [text block]
10. OTHER INVESTMENT, INCLUDING
Disclosure of issued capital [text block]
Share Capital
Disclosure of liquidity risk [text block]
5
Disclosure of loans and advances to customers [text block]
3
Disclosure of market risk [text block]
5
Disclosure of material accounting policy information [text block]
2. SUMMARY OF MATERIAL
Disclosure of objectives, policies and processes for managing capital [text block]
14
Disclosure of other liabilities [text block]
15
Disclosure of other operating income [text block]
21. OTHER OPERATING INCOME
Disclosure of prepayments and other assets [text block]
12. PREPAYMENTS
Disclosure of related party [text block]
28. RELATED PARTY TRANSACTIONS
Disclosure of research and development expense [text block]
Expenses by nature represent an alternative
Disclosure of reserves within equity [text block]
Other reserves
Disclosure of revenue [text block]
18. REVENUE
Disclosure of information about separate financial statements [text block]
Statement of Financial Position
Disclosure of share capital, reserves and other equity interest [text block]
14. EQUITY
Disclosure of share-based payment arrangements [text block]
25. SHARE-BASED PAYMENTS
Disclosure of subsidiaries [text block]
6. LIST OF CONSOLIDATED COMPANIES AS AT DECEMBER 31, 2023
Disclosure of tax receivables and payables [text block]
23
Disclosure of trade and other payables [text block]
16. TRADE AND OTHER LIABILITIES

Talk to a Data Expert

Have a question? We'll get back to you promptly.